Login to Your Account



Seeking Velcade successor, Takeda starts phase III trials of oral proteasome inhibitor

By Cornelia Zou
Staff Writer

Wednesday, February 5, 2014

HONG KONG – Looking to solidify its pipeline and extend patent protection for some of its top selling oncology products, Takeda Pharmaceutical Co. has launched a series of late-stage trials, including a Phase III clinical trial in Asia for its oral proteasome inhibitor MLN9708 (ixazomib citrate). Much of the work will be done in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription